INTERIM REPORT 2024

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024

Articles of Association

Boan Biotech Announces 2024 Half Year Results: Revenue Grows by 39%, Net Profit Increases by RMB 180 Million

YANTAI, China, Aug. 27, 2024-- Boan Biotech (6955.HK) today announced its 2024 half-year results and latest developments.During the reporting period, the company's total revenue was RMB 363 millio...

ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Notice of Board Meeting

Next Day Disclosure Return

Completion of Placing of New Shares under General Mandate

Boan’s Dulaglutide Cleared by FDA for Clinical Trials

Boan Biotech today announced that it has received the U.S. FDA clearance for clinical trials of its dulaglutide injection (BA5101). BA5101 is a proposed biosimilar to Trulicity® intended for glycemic ...